pharma · Major Depressive Disorder (MDD) · Primary or advanced breast cancer LumA or ER+ Lobular subtypes.
Talon Biomarkers
Talion
Talion is a pharma organization headquartered in JP. Primary therapeutic focus areas include Major Depressive Disorder (MDD), Primary or advanced breast cancer LumA or ER+ Lobular subtypes., non-small cell lung cancer (N
Whippany, USA HQ
2021 Founded
7 Employees
PMDA registrant Type
Company details
- Status
- Public
- HQ
- Whippany, USA
- Founded
- 2021
- Employees
- 7
- Programs
- 5
- Drugs
- 44
- Patents
- 0
PRIN - 20227EA9AN
Phase 3 · small molecule · Major Depressive Disorder (MDD)
PRIN - 20227EA9AN for Major Depressive Disorder (MDD) is a Phase 3 program (small_molecule) at Talion with 1 ClinicalTrials.gov record(s).
Internal code PRIN - 20227EA9AN
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Talion
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Major Depressive Disorder (MDD)
- Status
- active
- Trials
- 1